IP Library Granted Patent US 11,519,012
Granted Patent B2
US 11,519,012 · App. 16/614,566 · Granted Dec 6, 2022

Genomic engineering of biosynthetic pathways leading to increased NADPH

Inventors: Shawn Manchester (Oakland, CA); Benjamin Mason (Oakland, CA); Alexi Goranov (Oakland, CA)
Assignee: Zymergen Inc.
C12P13/08C12Y102/01011C12Y102/01012C12Y104/01003C12Y105/01017C12Y401/02042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,519,012
App. No.
16/614,566
Granted
Dec 6, 2022
Kind
B2
Abstract

The disclosure relates to host cells having altered NADPH availability, allowing for increased production of compounds produced using NADPH, and methods of use thereof. NADPH availability is altered by one or more of: expressing an altered GAPDH, expressing a variant glutamate dehydrogenase (gdh), aspartate semialdehyde dehydrogenase (asd), dihydropicolinate reductase (dapB), and meso-diaminopimelate dehydrogenase (ddh), expressing a novel nicotinamide nucleotide transhydrogenase, expressing a novel threonine aldolase, and expressing or modulating the expression of a pyruvate carboxylase in the host cells.

Claims (25)

1. A method of improving a microbial cell's ability to produce L-lysine, the method comprising altering the microbial cell's available NADPH by genetically modifying the microbial cell to express:

a) an aldehyde dehydrogenase from Lactobacillus agilis comprising SEQ ID NO: 30 or an aspartate-semi-aldehyde dehydrogenase from C. glutamicum comprising SEQ ID NO:40;

b) an glutamate dehydrogenase from Clostridium symbiosum comprising SEQ ID NO: 44;

c) a 4-hydroxy-tetrahydrodipicolinate reductase from Escherichia coli comprising SEQ ID NO: 48; and

d) a meso-diaminopimelate D-dehydrogenase from C. glutamicum comprising SEQ ID NO: 4,

wherein the microbial cell produces at least 40% more L-Lysine than a microbial cell that does not contain a)-d).

2. The method of claim 1 , wherein the microbial cell is a microbial cell selected from the group consisting of Corynebacterium cell, Escherichia cell, Bacillus cell and Geobacillus cell.

3. The method of claim 1 , wherein the microbial cell is a Corynebacterium glutamicum cell or an Escherichia coli cell.

4. The method of claim 1 , wherein the bacteria is E. coli and the method further comprises expressing a pyruvate carboxylase (pyc) in the E. coli cell.

5. The method of claim 1 , wherein the microbial cell is a Corynebacterium cell.

6. The method of claim 1 , wherein the microbial cell is an Escherichia cell.

7. The method of claim 1 , herein the microbial cell is a Bacillus cell.

8. The method of claim 1 , wherein the microbial cell is a Geobacillus cell.

9. The method of claim 1 , wherein the method comprises altering the microbial cell's available NADPH by genetically modifying the microbial cell to express:

a) an aldehyde dehydrogenase Lactobacillus agilis comprising SEQ ID NO: 30;

b) an glutamate dehydrogenase from Clostridium symbiosum comprising SEQ ID NO: 44;

c) a 4-hydroxy-tetrahydrodipicolinate reductase from Escherichia coli comprising SEQ ID NO: 48; and

d) a meso-diaminopimelate D-dehydrogenase from C. glutamicum comprising SEQ ID NO: 4.

10. The method of claim 9 , wherein the microbial cell is a Corynebacterium cell.

11. The method of claim 1 , wherein the method comprises altering the microbial cell's available NADPH by genetically modifying the microbial cell to express:

a) an aspartate-semi-aldehyde dehydrogenase from C. glutamicum comprising SEQ ID NO:40;

b) an glutamate dehydrogenase from Clostridium symbiosum comprising SEQ ID NO: 44;

c) a 4-hydroxy-tetrahydrodipicolinate reductase from Escherichia coli comprising SEQ ID NO: 48; and

d) a meso-diaminopimelate D-dehydrogenase from C. glutamicum comprising SEQ ID NO: 4.

12. The method of claim 11 , wherein the microbial cell is a Corynebacterium cell.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2022
From: PERCEPTIVE CREDIT HOLDINGS II, LP, AS ADMINISTRATIVE AGENT
To: ZYMERGEN INC.
Reel/Frame 061060/0024 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: MANCHESTER, SHAWN; MASON, BENJAMIN; GORANOV, ALEXI
To: ZYMERGEN INC.
Reel/Frame 051825/0363 →
Continuity (2)
Provisional Application 62508589 · May 19, 2017
Related Publication 20200263214A1 · Aug 20, 2020